Skip to content
Disclosery

CHI Advisors LLC

Follow

13F filer, CIK 1791468, NEW YORK, NY

CHI Advisors LLC reported $329,562,630 across 26 holdings for the quarter ended 2023-06-30, in a 13F-HR/A filed 2023-08-22. Its ten largest share positions make up 86.21% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR/A 0001085146-23-003476

Period
2023-06-30
Reported value
$330M
Holdings
26
Top 10 weight
86.21%
New
9
Sold out
7

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ACELYRIN INCnew+2,663,806$55.7M
KROSadded+141,059$5.67M
IRONnew+125,139$5.56M
DIREXION SHS ETF TRnew+325,000$4.67M
RAREnew+85,000$3.92M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
PROMETHEUS BIOSCIENCES INCexited-934,135-$100M
VECTIVBIO HLDG AGreduced-2,472,728-$41.7M
CRVSreduced-2,139,402-$4.9M
CHINOOK THERAPEUTICS INCexited-135,000-$3.13M
KEZAR LIFE SCIENCES INCexited-689,451-$2.16M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2023

Share positions as resolved from 13F-HR/A 0001085146-23-003476, largest first. % of portfolio is the value over $329,400,802, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PLRXPLIANT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: 2,569,479 shares; 2022Q1: 2,657,457 shares; 2022Q2: 3,106,807 shares; 2022Q3: 3,409,758 shares; 2022Q4: 3,169,892 shares; 2023Q1: 3,001,835 shares; 2023Q2: 3,117,017 shares 3,117,017$56.5M17.15%+115,182Timeline
ACELYRIN INCACELYRIN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: not reported; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 2,663,806 shares 2,663,806$55.7M16.9%new
VECTIVBIO HLDG AGVECTIVBIO HLDG AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: 2,675,408 shares; 2022Q1: 3,084,310 shares; 2022Q2: 3,782,199 shares; 2022Q3: 4,119,572 shares; 2022Q4: 5,492,893 shares; 2023Q1: 5,255,484 shares; 2023Q2: 2,782,756 shares 2,782,756$46.9M14.25%-2,472,728
CGEMCULLINAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: 2,476,720 shares; 2022Q1: 2,753,047 shares; 2022Q2: 3,047,609 shares; 2022Q3: 3,243,185 shares; 2022Q4: 3,317,544 shares; 2023Q1: 3,349,460 shares; 2023Q2: 3,414,189 shares 3,414,189$36.7M11.15%+64,729Timeline
REPARE THERAPEUTICS INCREPARE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: 2,212,256 shares; 2022Q1: 2,581,097 shares; 2022Q2: 2,646,781 shares; 2022Q3: 3,069,847 shares; 2022Q4: 2,800,126 shares; 2023Q1: 2,997,939 shares; 2023Q2: 2,998,734 shares 2,998,734$31.7M9.63%+795
KROSKEROS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: 17,518 shares; 2022Q1: 62,229 shares; 2022Q2: 103,429 shares; 2022Q3: 200,229 shares; 2022Q4: 215,059 shares; 2023Q1: 261,059 shares; 2023Q2: 402,118 shares 402,118$16.2M4.9%+141,059Timeline
IKENA ONCOLOGY INCIKENA ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: 814,756 shares; 2022Q1: 814,755 shares; 2022Q2: 1,090,937 shares; 2022Q3: 1,214,304 shares; 2022Q4: 1,637,372 shares; 2023Q1: 1,660,872 shares; 2023Q2: 2,122,040 shares 2,122,040$13.9M4.23%+461,168
CMPXCOMPASS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: 3,023,692 shares; 2022Q1: 2,829,712 shares; 2022Q2: 2,829,712 shares; 2022Q3: 2,829,712 shares; 2022Q4: 2,829,712 shares; 2023Q1: 2,829,712 shares; 2023Q2: 2,829,712 shares 2,829,712$9M2.73%0Timeline
LRMRLARIMAR THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: 1,515,148 shares; 2022Q1: 1,515,148 shares; 2022Q2: 1,515,148 shares; 2022Q3: 3,415,148 shares; 2022Q4: 3,473,366 shares; 2023Q1: 2,746,265 shares; 2023Q2: 3,414,468 shares 3,414,468$8.72M2.65%+668,203Timeline
2SEVENTY BIO INC COMMON STO…2SEVENTY BIO INC COMMON STOCKQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: not reported; 2022Q1: 819,672 shares; 2022Q2: 819,672 shares; 2022Q3: 530,223 shares; 2022Q4: 333,252 shares; 2023Q1: 855,000 shares; 2023Q2: 852,007 shares 852,007$8.62M2.62%-2,993
INOZYME PHARMA INCINOZYME PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: 892,057 shares; 2022Q1: 892,057 shares; 2022Q2: 2,033,802 shares; 2022Q3: 1,996,277 shares; 2022Q4: 2,204,876 shares; 2023Q1: 1,342,191 shares; 2023Q2: 1,195,027 shares 1,195,027$6.66M2.02%-147,164
OMEGA THERAPEUTICS INCOMEGA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: 1,055,882 shares; 2022Q1: 1,055,882 shares; 2022Q2: 1,055,882 shares; 2022Q3: 1,055,882 shares; 2022Q4: 1,055,882 shares; 2023Q1: 1,055,882 shares; 2023Q2: 1,055,882 shares 1,055,882$5.91M1.8%0
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: not reported; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 125,139 shares 125,139$5.56M1.69%newTimeline
DIREXION SHS ETF TRDIREXION SHS ETF TRQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: 50,000 shares; 2022Q4: 25,000 shares; 2023Q1: not reported; 2023Q2: 325,000 shares 325,000$4.67M1.42%new
ORCHARD THERAPEUTICS PLCORCHARD THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: not reported; 2022Q4: not reported; 2023Q1: 785,738 shares; 2023Q2: 755,738 shares 755,738$3.94M1.2%-30,000
RAREULTRAGENYX PHARMACEUTICAL INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: not reported; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 85,000 shares 85,000$3.92M1.19%newTimeline
BDTXBLACK DIAMOND THERAPEUTICS IQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: not reported; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 750,000 shares 750,000$3.79M1.15%newTimeline
RALLYBIO CORPRALLYBIO CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: 194,297 shares; 2022Q4: 726,109 shares; 2023Q1: 760,543 shares; 2023Q2: 542,774 shares 542,774$3.07M0.93%-217,769
OVIDOVID THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: 400,000 shares; 2022Q1: 852,888 shares; 2022Q2: 864,822 shares; 2022Q3: 864,822 shares; 2022Q4: 864,822 shares; 2023Q1: 864,822 shares; 2023Q2: 864,822 shares 864,822$2.84M0.86%0Timeline
SYRSSYROS PHARMACEUTICALS INC COMQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: not reported; 2022Q4: not reported; 2023Q1: 767,445 shares; 2023Q2: 767,445 shares 767,445$2.42M0.73%0Timeline
PRECISION BIOSCIENCES INCPRECISION BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: 606,629 shares; 2022Q1: 606,629 shares; 2022Q2: 3,003,751 shares; 2022Q3: 3,674,820 shares; 2022Q4: 3,549,820 shares; 2023Q1: 3,469,820 shares; 2023Q2: 1,603,557 shares 1,603,557$843K0.26%-1,866,263
HOOKIPA PHARMA INCHOOKIPA PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: not reported; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 788,740 shares 788,740$694K0.21%new
GRAPHITE BIO INCGRAPHITE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: not reported; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 230,938 shares 230,938$600K0.18%new
CRVSCORVUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: 400,000 shares; 2022Q1: 1,703,137 shares; 2022Q2: 2,214,184 shares; 2022Q3: 2,384,402 shares; 2022Q4: 2,384,402 shares; 2023Q1: 2,339,402 shares; 2023Q2: 200,000 shares 200,000$458K0.14%-2,139,402Timeline
FREELINE THERAPEUTICS HLDGSFREELINE THERAPEUTICS HLDGSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: not reported; 2022Q1: not reported; 2022Q2: not reported; 2022Q3: not reported; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 21,666 shares 21,666$55.9K0.02%new

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
PLRXPLIANT THERAPEUTICS INC COMcall130,300$162Knew

Sold out in Q2 2023

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
PROMETHEUS BIOSCIENCES INCPROMETHEUS BIOSCIENCES INC934,135$100Mshares
CHINOOK THERAPEUTICS INCCHINOOK THERAPEUTICS INC135,000$3.13Mshares
KEZAR LIFE SCIENCES INCKEZAR LIFE SCIENCES INC689,451$2.16Mshares
FREELINE THERAPEUTICS HLDGSFREELINE THERAPEUTICS HLDGS4,729,419$2.15Mshares
TRDAENTRADA THERAPEUTICS INC56,374$817Kshares
ONCORUS INCONCORUS INC2,367,436$815Kshares
PROMETHEUS BIOSCIENCES INCPROMETHEUS BIOSCIENCES INC25,000$108Kcall

How Q2 2023 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001085146-23-003260 superseded2023-08-11acceptance time not in the bulk data set
13F-HR/A 0001085146-23-003476 baserestatement2023-08-22acceptance time not in the bulk data set